PHE Weekly National Influenza Report

Summary of UK surveillance of influenza and other seasonal respiratory illnesses

21 March 2019 – Week 12 report (up to week 11 data)

This report is published weekly on the PHE website. For further information on the surveillance schemes mentioned in this report, please see the PHE website and the related links at the end of this document.

| Summary | Community surveillance | GP consultation rates | Hospitalisations | All-cause mortality | Microbiological surveillance | Vaccination | International | Acknowledgements | Related links |

Summary – Week 11 (ending 17 March 2019)

- During week 11, influenza continued to circulate in the community with activity indicators decreasing and Below Baseline.
- The impact of flu on healthcare services is at Medium impact for hospitalisations and Low for ICU/HDU influenza admissions.
- Influenza A(H1N1)pdm09 and influenza A(H3N2) are co-circulating. The Department of Health & Social Care has issued an alert on the prescription of antiviral medicines by GPs.

### Community

- Thirty-eight new acute respiratory outbreaks have been reported in the past 7 days. Thirty-four outbreaks were reported from care homes where 12 tested positive for influenza A(not subtyped), 1 human metapneumovirus (hMPV) and 1 co-infection of influenza A(H1N1)pdm09, hMPV and influenza A(not subtyped). Two outbreaks were reported from hospitals where 1 tested positive for influenza A(not subtyped). Two outbreaks were reported from schools where one tested positive for influenza B.

### Primary Care

- The rate of influenza-like illness (ILI) was Below Baseline threshold levels. The overall weekly ILI GP consultation rate was 6.2 per 100,000 registered population in participating GP practices for England, this is a decrease from 9.1 per 100,000 in week 10 2019.
- In the devolved administrations, ILI rates were Below Baseline threshold levels for Northern Ireland, Scotland and Wales.

### Secondary Care

- Hospitalisation rate observed was at Medium impact levels, with a rate of 1.52 per 100,000 trust catchment population for England (19 NHS Trusts), this is a slight decrease from 1.56 per 100,000 in week 10.
- ICU/HDU admission rate observed was at Low impact levels, with a rate of 0.09 per 100,000 trust catchment population for England (136/143 NHS Trusts), this is a decrease from 0.20 per 100,000 in week 10.
- There was no new laboratory confirmed influenza admissions reported from the 6 Severe Respiratory Failure centres in the UK.

### All-cause mortality

- In week 11 2019, no statistically significant excess all-cause mortality by week of death was seen overall and by age group in England. In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Wales and Northern Ireland in week 11 and in Scotland in week 09 2019.

### Microbiological surveillance

- **Primary care**: Two samples tested positive for influenza (2 influenza A(H1N1)pdm09) with a positivity of 16.7% through the UK GP sentinel swabbing schemes in week 11 2019.
- **Secondary care**: Influenza percent positivity was 13.4%, Above Baseline threshold level, this is a slight increase from 11.5% in week 10. There were 250 detections recorded through the DataMart scheme (22 influenza A(H1N1)pdm09, 157 influenza A(H3), 68 influenza A(not subtyped) and 3 influenza B).

### Vaccination

- Provisional data from the fourth monthly collection of influenza vaccine uptake in GP patients shows that in 99.6% of GP practices the proportions of people in England who had received the 2018/19 influenza vaccine in targeted groups by 31 January 2019 were: 46.9% in under 65 years in a clinical risk group, 45.0% in pregnant women and 71.3% in 65+ year olds. In 99.4% of GP practices reporting for the childhood collection the provisional proportions vaccinated by 31 January 2019 were: 43.1% in 2 year olds and 45.2% in 3 year olds.
- Provisional data from the fifth monthly collection of influenza vaccine uptake by frontline healthcare workers show 70.3% were vaccinated by 28 February 2019, compared to 68.7% vaccinated in the previous season by 28 February 2018.
- Provisional data from the fourth monthly collection of influenza vaccine uptake for children of school years reception to year 5 shows 63.9% in school year reception age, 63.4% in school year 1 age, 61.4% in school year 2 age, 60.2% in school year 3 age, 58.0% in school year 4 age and 56.2% in school year 5 age were vaccinated by 31 January 2019.
- **WHO** have published their recommendations for the composition of the 2019/20 Northern hemisphere influenza vaccine.

### International situation

- In the temperate zone of the Northern hemisphere, influenza activity continued to be reported with influenza A viruses predominating overall. In the temperate zones of the Southern hemisphere, influenza activity remained at inter-seasonal levels, with the exception of some parts of Australia which remained above inter-seasonal levels. Worldwide, seasonal influenza subtype A viruses accounted for the majority of detections.

**Key**

| Arrows (vs previous week): Colour (intensity according to MEM threshold): |
|--------------------------|-------|
| Increase                 | Below Baseline |
| Decrease                 | High |
| Stable/No trend          | Above Baseline/Low |
|                          | Very High |
|                          | Medium |
Thirty-eight new acute respiratory outbreaks were reported in the past 7 days.

- Acute respiratory disease outbreaks
  - Thirty-eight new acute respiratory outbreaks have been reported in the past 7 days. Thirty-four outbreaks were reported from care homes where 12 tested positive for influenza A (not subtyped), 1 human metapneumovirus (hMPV) and 1 co-infection of influenza A(H1N1)pdm09, hMPV and influenza A (not subtyped). Two outbreaks were reported from hospitals where 1 tested positive for influenza A (not subtyped). Two outbreaks were reported from schools where one tested positive for influenza B.
  - Outbreaks should be recorded on HPZone and reported to the local Health Protection Teams and respсидsc@phe.gov.uk

- Medical Officers of Schools Association (MOSA) & PHE surveillance scheme
  - Boarding schools in England within the MOSA network are recruited each season to report various respiratory related illnesses including influenza like illnesses (ILI). For the 2018/19 season, 21 MOSA schools have agreed to participate in the scheme, including a total of 6,661 boarders.
  - The overall rate (all boarders) for week 10 was 0.0 per 1,000 boarders compared to 0.6 per 1,000 boarders in week 09.
  - Since week 40, there have been 16 outbreaks reported from 10 MOSA schools, with a total of 59 ILI cases identified. Of the 16 outbreaks, 2 outbreaks have tested positive for influenza A (H1N1)pdm09 and 1 outbreak has tested positive for influenza B.
  - If you are a MOSA school and would like to participate in this scheme, please email mosa@phe.gov.uk for more information.

- FluSurvey
  - Internet-based surveillance of influenza-like illness in the general population is undertaken through FluSurvey. A project run by PHE to monitor ILI activity in the community.
  - The overall ILI rate (all age groups) for week 11 2019 was 19.4 per 1,000 (45/2,317 people reported at least 1 ILI) (Figure 3) compared to 18.2 per 1,000 in the previous week, with the highest rate seen in the 20-44 year olds (23.7 per 1,000).
  - If you would like to become a participant of the FluSurvey project please do so by visiting the https://flusurvey.net/en/accounts/register/ website for more information.
In week 11, the overall weekly influenza-like illness (ILI) GP consultation rate continued to decrease with ILI rate below baseline threshold levels in England. In the devolved administrations, ILI rates decreased compared to week 10 and are below their respective baselines in Scotland, Northern Ireland and Wales.

- GP ILI consultations in the UK

**RCGP (England)**
- The weekly ILI consultation rate through the RCGP surveillance was at 6.2 per 100,000 registered population in participating GP practices in week 11 2019, this is a decrease from 9.1 per 100,000 in week 10. This is below the baseline threshold (13.1 per 100,000) (Figure 4*). By age group, the highest rates were seen in 15-44 year olds (7.5 per 100,000) and in 45-64 year olds (7.0 per 100,000).

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10) in a standardised approach across Europe. For MEM intensity threshold values, please visit: https://www.gov.uk/guidance/sources-clinical-surveillance-in-the-uk#clinical-surveillance-through-primary-care

**UK**
- In week 11, overall weekly ILI consultation rates across countries of the UK decreased compared to the previous week, with all countries below their respective baseline threshold levels (Table 1).
- By age group, the highest rates were seen in the 45-64 year olds in Scotland and Northern Ireland (8.2 per 100,000 and 8.1 per 100,000 respectively) and in the 15-44 year olds in Wales (10.4 per 100,000).

**Table 1: GP ILI consultations in the UK for all ages with MEM thresholds applied**

<table>
<thead>
<tr>
<th>GP ILI consultation rates (all ages)</th>
<th>40</th>
<th>41</th>
<th>42</th>
<th>43</th>
<th>44</th>
<th>45</th>
<th>46</th>
<th>47</th>
<th>48</th>
<th>49</th>
<th>50</th>
<th>51</th>
<th>52</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
</tr>
</thead>
<tbody>
<tr>
<td>England (RCGP)</td>
<td>4.2</td>
<td>3.9</td>
<td>4.5</td>
<td>3.5</td>
<td>5.3</td>
<td>5.6</td>
<td>6.4</td>
<td>5.8</td>
<td>7.6</td>
<td>8.5</td>
<td>9.4</td>
<td>9.5</td>
<td>14.6</td>
<td>19.2</td>
<td>19.6</td>
<td>17.5</td>
<td>19.2</td>
<td>23.1</td>
<td>21.1</td>
<td>15.2</td>
<td>21.5</td>
<td>33.9</td>
<td>62.3</td>
<td></td>
</tr>
<tr>
<td>Wales</td>
<td>7.0</td>
<td>3.6</td>
<td>4.2</td>
<td>6.6</td>
<td>6.3</td>
<td>6.4</td>
<td>4.5</td>
<td>4.7</td>
<td>6.5</td>
<td>3.2</td>
<td>4.5</td>
<td>9.0</td>
<td>9.5</td>
<td>14.7</td>
<td>20.5</td>
<td>22.9</td>
<td>15.7</td>
<td>20.5</td>
<td>21.4</td>
<td>17.2</td>
<td>17.5</td>
<td>4.2</td>
<td>8.7</td>
<td>7.5</td>
</tr>
<tr>
<td>Scotland</td>
<td>7.1</td>
<td>5.6</td>
<td>4.0</td>
<td>3.8</td>
<td>2.6</td>
<td>7.6</td>
<td>4.0</td>
<td>4.7</td>
<td>5.6</td>
<td>4.0</td>
<td>6.5</td>
<td>10.1</td>
<td>8.9</td>
<td>17.3</td>
<td>26.7</td>
<td>18.0</td>
<td>28.4</td>
<td>32.7</td>
<td>32.3</td>
<td>27.2</td>
<td>20.8</td>
<td>12.2</td>
<td>10.2</td>
<td>6.3</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>5.8</td>
<td>3.5</td>
<td>3.6</td>
<td>3.6</td>
<td>3.0</td>
<td>6.3</td>
<td>4.5</td>
<td>5.6</td>
<td>6.0</td>
<td>8.4</td>
<td>8.5</td>
<td>9.5</td>
<td>10.5</td>
<td>18.8</td>
<td>14.4</td>
<td>12.4</td>
<td>14.5</td>
<td>18.2</td>
<td>16.5</td>
<td>11.1</td>
<td>9.0</td>
<td>5.9</td>
<td>5.6</td>
<td></td>
</tr>
</tbody>
</table>

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10), in a standardised approach across Europe. For MEM threshold values for each country, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#clinical-surveillance-through-primary-care

**GP In Hours Syndromic Surveillance System (England)**
- The weekly ILI consultation rate through the GP In Hours Syndromic Surveillance system is at 5.3 per 100,000 in week 11 2019 (Figure 5).
- During week 11, NHS 111 cold/flu calls and GPOOH consultations remained at pre-epidemic levels. There were further small decreases noted in ED attendances for ILI. GPIH for ILI also continued to decrease and remain below the pre-epidemic threshold.
- Figure 5 represents a map of GP ILI consultation rates in week 11 across England by PHE centres, with influenza-like illness surveillance MEM thresholds applied.

ILI consultation rates presented for each uL A on the map should be interpreted in context of regional and national ILI activity, as MEM thresholds are calculated (based on previous influenza seasons from 2012/13 onwards) separately for each of the nine PHE centres and uL A rates are then compared to Centre-level thresholds only, therefore u L A s with higher background rates than the Centre may appear to have higher ILI activity.

- For further information, please see the syndromic surveillance webpage.
In week 11 2019, there were 137 hospitalised influenza cases (19 influenza A(H1N1)pdm09, 51 influenza A(H3N2), 66 influenza A(unknown) and one influenza B) reported through the USISS sentinel hospital network across England (21 NHS Trusts). There were 47 new admissions to ICU/HDU with confirmed influenza (11 influenza A(H1N1)pdm09, 4 influenza A (H3N2), 32 influenza A(unknown subtype)) reported through the USISS mandatory ICU/HDU surveillance scheme across the UK (136/143 NHS Trusts in England).

- **USISS sentinel weekly hospitalised confirmed influenza cases, England (week 11)**

  - In week 11 2019, there were 137 hospitalised laboratory confirmed influenza cases (19 influenza A(H1N1)pdm09, 51 influenza A(H3N2), 66 influenza A(unknown) and one influenza B) reported from 19 NHS Trusts across England through the USISS sentinel hospital network, with a rate of 1.52 per 100,000 trust catchment population compared to 1.56 per 100,000 in the previous week (Figures 6 and 7). This is within the medium impact range of 1.22 to <5.08 per 100,000.
  
  - A total of 5,130 hospitalised confirmed influenza cases in ICU/HDU (USISS mandatory) by age group and flu type, UK (week 11), there were 47 new admissions to ICU/HDU with confirmed influenza (11 influenza A(H1N1)pdm09, 4 influenza A (H3N2), 32 influenza A(unknown subtype)) and 33 influenza B) have been reported in the England since week 40 2018 via the sentinel scheme.

- **Number of new admissions and fatal confirmed influenza cases in ICU/HDU (USISS mandatory ICU scheme), UK (week 11)**

  - In week 11 2019, there were 47 new admissions to ICU/HDU with confirmed influenza (11 influenza A(H1N1)pdm09, 4 influenza A (H3N2) and 32 influenza A(unknown subtype)) reported through the USISS mandatory ICU scheme in the UK (136/143). The rate for England (n=45) was 0.09 per 100,000 trust catchment population (Figures 8 and 9) compared to 0.20 per 100,000 in week 10 2019). Five fatal influenza cases in ICU were reported in week 11 2019 in the UK.

  - A total of 2,999 new admissions (976 influenza A(H1N1)pdm09, 186 influenza A(H3N2), 1,808 influenza A(unknown subtype) and 29 influenza B) and 293 confirmed deaths have been reported in the UK since week 40 2018.

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for ICU/HDU admission rates for the start of influenza activity (based on 6 seasons) in a standardised approach across Europe. For MEM threshold values, please visit: [https://www.gov.uk/guidance/sources](https://www.gov.uk/guidance/sources)
Excess all-cause mortality by age group, England, Wales, Scotland and Northern Ireland

In week 11 2019 in England, no statistically significant excess all-cause mortality by week of death was observed overall and by age group in England, through the EuroMOMO algorithm. In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Wales and Northern Ireland in week 11 2019 and in Scotland in week 09 2019.

In week 10 2019, an estimated 10,898 all-cause deaths were registered in England and Wales (source: Office for National Statistics). This is a decrease compared to the 11,044 estimated death registrations in week 09 2019.

In week 11 2019 in England, no statistically significant excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group and sub-nationally (all ages), after correcting ONS disaggregate data for reporting delay with the standardised EuroMOMO algorithm. This data is provisional due to the time delay in registration; numbers may vary from week to week.

In the devolved administrations, statistically significant excess all-cause mortality for all ages was observed in Wales and Northern Ireland in week 11 2019 and in Scotland in week 09 2019 (Table 2).

USISS Severe Respiratory Failure Centre confirmed influenza admissions, UK (week 10)

- In week 11, there was no new admissions for laboratory confirmed influenza among the 6 Severe Respiratory Failure (SRF) centres in the UK.
- Since week 40 2018, there have been 92 confirmed influenza admissions (76 influenza A(H1N1)pdm09, 4 influenza A(H3N2) and 12 influenza A(unknown subtype)) to ECMO centres.

Figure 10: Weekly observed and expected number of all-age all-cause deaths, with the dominant circulating influenza A subtype, England, 2014 to week 11 2019

*Note: Delays in receiving all registered deaths from April 2018, following changes in IT systems at ONS, may result in some delays in the model to adjust for most recent deaths.
In week 11 2019, two samples tested positive for influenza (2 influenza A(H1N1)pdm09) with a positivity of 16.7% through the UK GP sentinel schemes. 250 positive detections were recorded through the DataMart scheme (22 influenza A(H1N1)pdm09, 157 influenza A(H3), 68 influenza A(not subtyped) and 3 influenza B) with a positivity of 13.4%, this is above the baseline threshold of 9.2%.

- **Sentinel swabbing schemes in England (RCGP) and the Devolved Administrations**
  - In week 11 2019, two samples tested positive for influenza (2 influenza A(H1N1)pdm09) with an overall positivity of 16.7% compared to 24.6% in week 10 2019 through the UK GP sentinel swabbing schemes (Figure 11).

Since week 40, a total of 826 samples (643 influenza A(H1N1)pdm09, 156 influenza A(H3), 19 influenza A(unknown subtype) and 8 influenza B) tested positive for influenza through this scheme.

- **Respiratory DataMart System (England)**
  - In week 11 2019, out of the 1,860 respiratory specimens reported through the Respiratory DataMart System, 250 samples were positive for influenza (22 influenza A(H1N1)pdm09, 157 influenza A(H3), 68 influenza A(not subtyped) and 3 influenza B) (Figure 12), with an overall positivity of 13.4% compared to 11.5% the previous week, which is above the MEM baseline threshold for this season of 9.2%. The highest positivity for influenza by age group was seen in the 15-44 year olds at 16.1% in week 11 (Figure 13).

RSV positivity remained low. Rhinovirus positivity increased slightly from 8.8% in week 10 to 11.7% in week 11 2019. Human metapneumovirus (hMPV) and parainfluenza positivities increased slightly to 4.2% and 5.5% respectively in week 11. Adenovirus positivity remained stable at 3.9% in week 11 (Figure 14).

*The Moving Epidemic Method has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity in a standardised approach across Europe. The threshold to indicate a likelihood of influenza community circulation for Datamart % positive as calculated through the Moving Epidemic Method is 9.2% in 2018/19.*
- **Virus characterisation**

PHE characterises the properties of influenza viruses through one or more tests, including *genome sequencing* (genetic analysis) and *haemagglutination inhibition (HI)* assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

The PHE Respiratory Virus Unit has characterised 722 influenza A(H1N1)pdm09 viruses detected since week 40. Genetic characterisation of 674 influenza A(H1N1)pdm09 viruses detected since week 40 shows that they all belong in the genetic subgroup 68.1, which was the predominant genetic subgroup in the 2017/18 season. Two-hundred and forty-six A(H1N1)pdm09 viruses have been antigenically characterised and are similar to the A/Michigan/45/2015-like Northern Hemisphere 2018/19 (H1N1)pdm09 vaccine strain.

Genetic characterisation of 140 A(H3N2) influenza viruses shows that they all belong to genetic subclade 3C.2a, with 134 belonging to a cluster within this genetic subclade designated as 3C.2a1. One virus belonging to the genetic subclade 3C.3a was detected. The Northern Hemisphere 2018/19 influenza A(H3N2) vaccine strain belongs in genetic subclade 3C.2a1.

Of three influenza B viruses characterised to date, two influenza B viruses have been characterised where sequencing of the haemagglutinin (HA) gene shows they belong within genetic clade 1A of the B/Victoria lineage. One of them clusters in a subgroup characterised by deletion of two amino acids in the HA. The N.Hemisphere 2018/19 B/Victoria-lineage quadrivalent and trivalent vaccine component virus (a B/Colorado/06/2017-like virus), is a double deletion subgroup virus. The other influenza B virus has been characterised genetically as belonging to genetic clade 3 of the B/Yamagata lineage and antigenically as similar to the B/Phuket/3073/2013 B/Yamagata lineage vaccine component in the N.Hemisphere 2018/19 quadrivalent vaccine.

<table>
<thead>
<tr>
<th>Virus</th>
<th>No. viruses characterised</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Genetic and antigenic</td>
</tr>
<tr>
<td>A(H1N1)pdm09</td>
<td>198</td>
</tr>
<tr>
<td>A(H3N2)</td>
<td>0</td>
</tr>
<tr>
<td>B/Yamagata-lineage</td>
<td>1</td>
</tr>
<tr>
<td>B/Victoria-lineage</td>
<td>0</td>
</tr>
</tbody>
</table>

- **Antimicrobial susceptibility**

<table>
<thead>
<tr>
<th>Organism</th>
<th>Antibiotic</th>
<th>Specimens tested (N)</th>
<th>Specimens susceptible (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. pneumoniae</td>
<td>Penicillin</td>
<td>4682</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>5083</td>
<td>83</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>4983</td>
<td>86</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>Amoxicillin/amoxicillin</td>
<td>19208</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>Co-amoxiclav</td>
<td>20704</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>4138</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>20704</td>
<td>94</td>
</tr>
<tr>
<td>S. aureus</td>
<td>Methicillin</td>
<td>7207</td>
<td>91</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>8075</td>
<td>65</td>
</tr>
<tr>
<td>MRSA</td>
<td>Clindamycin</td>
<td>422</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>548</td>
<td>78</td>
</tr>
<tr>
<td>MSSA</td>
<td>Clindamycin</td>
<td>4432</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>6109</td>
<td>93</td>
</tr>
</tbody>
</table>

*Macrolides = erythromycin, azithromycin and clarithromycin*
• Up to week 04 2019, in 97.4% of GP practices reporting weekly to ImmForm, the provisional proportion of people in England who had received the 2018/19 influenza vaccine in targeted groups was as follows (Figure 15):
  o 46.7% in under 65 years in a clinical risk group
  o 44.8% in pregnant women
  o 71.2% in 65+ year olds

![Figure 15: Cumulative weekly influenza vaccine uptake by target group in England](image)

• In 2018/19, all 2 and 3 year olds continue to be eligible for flu vaccination, through their GPs.
Up to week 04 2019, in 97.5% of GP practices reporting weekly to ImmForm, the provisional proportion of children in England who had received the 2018/19 influenza vaccine in targeted groups was as follows (Figure 16):
  o 43.0% in 2 year olds
  o 45.0% in 3 year olds

![Figure 16: Cumulative weekly influenza vaccine uptake by target group in England](image)

• Provisional data from the fifth monthly collection of the influenza vaccine uptake by frontline healthcare workers show 70.3% were vaccinated by 28 February 2019 from 98.8% of all organisations, compared to 68.7% vaccinated in the previous season by 28 February 2018. The report provides uptake at national, NHS England local team and Trust-level.
• Provisional data from the fourth monthly collection of influenza vaccine uptake for children of school years Reception, 1, 2, 3, 4 and 5 age (from a sample of 100% of all Local Authorities in England) show the provisional proportion of children in England who received the 2018/19 influenza vaccine via school, pharmacy or GP practice by 31 January 2019 in targeted groups as follows:
  o 63.9% in children school year reception age (4-5 yrs) compared to 62.6% by 31 January 2018
  o 63.4% in children school year 1 age (5-6 yrs) compared to 60.9% by 31 January 2018
  o 61.4% in children school year 2 age (6-7 yrs) compared to 60.3% by 31 January 2018
  o 60.2% in children school year 3 age (7-8 yrs) compared to 57.5% by 31 January 2018
  o 58.0% in children school year 4 age (8-9 yrs) compared to 55.7% by 31 January 2018
  o 56.2% in children school year 5 age (9-10 yrs); age group not included in 2017/18 school vaccine programme.

• Provisional data from the fourth monthly collection of influenza vaccine uptake in GP patients up to 31 January 2019 show that in 99.6% of all GP practices in England responding to the main GP survey, the proportion of people in England who receive the 2018/19 influenza vaccine was as follows:
  o 46.9% under 65 year olds in a clinical risk group compared to 48.9% by 31 January 2018
  o 45.0% in pregnant women compared to 47.2% by 31 January 2018
  o 71.3% in 65+ year olds compared to 72.6% by 31 January 2018

• Provisional data from the fourth monthly collection of influenza vaccine uptake in GP patients up to 31 January 2019 show that in 99.4% of all GP practices in England responding to the child GP survey, the proportion of people in England who receive the 2018/19 influenza vaccine was as follows:
  o 43.1% in 2 year olds compared to 42.8% by 31 January 2018
  o 45.2% in 3 year olds compared to 44.2% by 31 January 2018

• The 2018/19 mid-season influenza vaccine effectiveness study was recently published. The report is based on 6 European studies including the UK, analysing influenza data from October 2018 to January 2019.

### International Situation

In the temperate zone of the Northern hemisphere, influenza activity continued to be reported with influenza A viruses predominating overall. In the temperate zones of the Southern hemisphere, influenza activity remained at inter-seasonal levels, with the exception of some parts of Australia where influenza activity remained above inter-seasonal levels. Worldwide, seasonal influenza subtype A viruses accounted for the majority of detections.

- **Europe** updated on 15 March 2019 (Joint ECDC-WHO Europe Influenza weekly update)

In week 10 2019, influenza activity was widespread in the European Region. Influenza A virus detections dominated with slightly more A(H1N1)pdm09 viruses than A(H3N2) viruses and very few influenza B viruses detected.

Of 46 Member States and areas reporting on intensity, 1 reported high intensity, 13 reported medium (northern, southern and western areas), 24 reported low intensity (across the region), and 8 reported baseline (eastern, northern, western areas) in week 10 2019.

Of 46 Member States and areas reporting on geographic spread, 20 reported widespread (in northern, southern, western areas), 13 reported regional spread (across the region), 5 reported local spread (Azerbaijan, Belarus, Russian Federation, Slovakia, Switzerland), 5 reported sporadic cases (Armenia, Hungary, Ireland, Israel, United Kingdom (Northern Ireland)), and 3 reported no activity (Bulgaria, Cyprus, Uzbekistan).

For week 10 2019, 786 (42.8%) of 1,836 sentinel specimens tested positive for an influenza virus; 774 were type A and 12 were type B. Of 425 subtyped A viruses, 44.5% were A(H1N1)pdm09 and 55.5% were A(H3N2). Of 3 type B viruses ascribed to a lineage, all were Yamagata lineage.

For week 10 2019, 181 laboratory-confirmed influenza cases were reported in ICUs. Of these, in 178 (98.3%) influenza type A viruses were detected almost exclusively. Among the 138 laboratory confirmed influenza cases in other wards reported, all were influenza type A viruses.

For week 10 2019, 7,574 specimens from non-sentinel sources (such as hospitals, schools, primary care facilities not involved in sentinel surveillance, or nursing homes and other institutions) tested positive for an influenza virus: 98.7% were type A and 1.3% were type B. Of 2, 418 subtyped A viruses, 48.4% were A(H1N1)pdm09 and 51.6% were A(H3N2)

For week 10 2019, data from the 22 Member States or areas reporting to the EuroMOMO project were included in pooled analyses. The pooled estimates indicated excess mortality among those aged 15-64 years and 65+ years observed in recent weeks has continued to decline.
• **United States of America** updated on 15 March 2019 (Centre for Disease Control report)

During week 10, influenza activity decreased slightly, but remains elevated in the United States. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses continue to co-circulate.

A cumulative rate of 41.3 laboratory-confirmed influenza-associated hospitalisations per 100,000 population was reported, with the highest rate among those aged 65+ years old.

Nationwide during week 10, the proportion of outpatient visits for influenza-like illness (ILI) decreased slightly 4.5% which remains above the national baseline of 2.2%.

For week 10, the proportion of deaths attributed to pneumonia and influenza (P&I) was 7.2%, below the epidemiologic threshold (7.3% for week 09) in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

Four influenza-associated pediatric deaths (1 influenza A(H1N1)pdm09, 2 influenza A(H3) and 1 influenza A(not subtyped)) were reported to the CDC during week 10.

• **Canada** updated on 15 March 2019 (Public Health Agency report)

Overall, influenza activity continues to be reported in almost all regions in Canada but is circulating at higher levels in eastern regions. Influenza A(H1N1)pdm09 has been the predominant subtype to date this season.

In week 10, a total of 1,803 laboratory confirmed detections of influenza were reported, of which 96% were influenza A, with influenza A(H3N2) accounting for 56% of subtyped A viruses. The percentage of tests positive for influenza from sentinel laboratories continued to increase slightly and was at 21.3%, which is above the seasonal threshold of 5.0%.

In week 10, 1.3% of visits to healthcare professionals were due to ILI, the percentage of visits for ILI is low compared to previous seasons.

To date this season, 2,351 influenza-associated hospitalisations have been reported by participating provinces and territories, of which 2,329 (99.1%) were associated with influenza A, with the highest estimated rate seen among children less than 5 years of age. To date this season, 429 ICU admissions and 109 deaths have been reported; all but 3 ICU admissions and all but 1 of the reported deaths were associated with influenza A, with the highest percentage reported in adults aged 45-64 years.

• **Global influenza update** updated on 18 March 2019 (WHO website)

In the temperate zone of the Northern hemisphere, influenza activity continued to be reported with influenza A viruses predominating overall. In the temperate zones of the Southern hemisphere, influenza activity remained at inter-seasonal levels, with the exception of some parts of Australia where influenza activity remained above inter-seasonal levels. Worldwide, seasonal influenza subtype A viruses accounted for the majority of detections.

In North America, influenza activity continued, with influenza A(H1N1)pdm09 as the dominant subtype followed by influenza A(H3N2) virus. In Canada, at national level, influenza activity increased slightly compared to the previous reporting period but remain low overall. In the United States, ILI activity started to decrease at the national level, but remained above the baseline. In Mexico, influenza activity appeared to decrease with all seasonal influenza subtypes co-circulating.

In Europe, influenza activity decreased across the continent, with still two thirds of countries above baseline for ILI activity. High intensity was reported in North Macedonia and Kosovo (in accordance with the Security Council resolution 1244 (1999)). Influenza activity remained elevated in some countries of Eastern Europe. Although influenza A(H1N1)pdm09 was the most frequently detected virus overall, influenza A(H3N2) viruses co-circulated and predominated in some countries.

In Central Asia, severe acute respiratory infections (SARI) levels remained elevated in Kazakhstan and Uzbekistan. Influenza detections of all seasonal influenza subtypes appeared to decrease in Kazakhstan.

In Northern Africa, influenza activity was reported in Algeria and Tunisia, with detections of both seasonal influenza A subtypes. In Egypt and Morocco, influenza detections and percent positive returned to low levels. In Western Asia, influenza activity decreased in most countries except in Armenia, Kuwait, Lebanon and Saudi Arabia, where activity remained elevated. Detections of all seasonal influenza subtypes were reported in the sub-region.
In East Asia, the influenza activity appeared to have plateaued after a decrease from the peak in week 03/2019. Although decreased, influenza activity remained above seasonal threshold in China and China, Hong Kong SAR. Influenza A(H1N1)pdm09 was the virus most frequently detected followed by influenza A(H3N2) and a smaller proportion of B Victoria-lineage.

In the Caribbean and Central American countries, influenza activity and respiratory syncytial virus (RSV) remained low overall. Increased detections of influenza A viruses were reported in Cuba and Jamaica.

In the tropical countries of South America, influenza and RSV activity were low in general.

In Western and Middle Africa, influenza detections were low across reporting countries. In Eastern Africa, influenza detections increased in Ethiopia, Kenya, Madagascar and Mauritius, with both influenza A virus subtypes co-circulating in the sub-region.

In Southern Asia, influenza activity remained elevated, with influenza A viruses predominating. In Afghanistan, SARI levels and influenza activity of predominately A(H1N1)pdm09 virus continued to decrease although ILI activity remained elevated. Influenza activity continued at high level in India with influenza A(H1N1)pdm09 virus most frequently detected followed by influenza A(H3N2) viruses. Influenza activity was reported in Nepal in recent weeks and appeared to have peaked at the end of January, with influenza A(H1N1)pdm09 predominating followed by a smaller proportion of influenza B viruses. In Pakistan, decreased influenza activity was reported with detections of all seasonal influenza subtypes.

In South East Asia, few countries reported in this reporting period. A sharp increase of influenza activity was reported in Thailand, with influenza B most frequently detected followed by influenza A viruses. Influenza activity appeared to decrease in the Philippines, with detections of predominantly influenza B Victoria-lineage virus.

The WHO GISRS laboratories tested more than 205,150 specimens between 18 February 2019 and 03 March 2019. 59,350 were positive for influenza viruses, of which 57,635 (97.1%) were typed as influenza A and 1,715 (2.9%) as influenza B. Of the sub-typed influenza A viruses, 14,751 (59.5%) were influenza A (H1N1)pdm09 and 10,037 (40.5%) were influenza A (H3N2). Of the characterized B viruses, 147 (19.0%) belonged to the B-Yamagata lineage and 625 (81.0%) to the B-Victoria lineage.

- **Avian Influenza** latest update on 25 February 2019 (WHO website)

**Influenza A(H5) viruses**
Between 21 January 2018 and 12 February 2019, no new laboratory-confirmed human cases of influenza A(H5) virus infections were reported to WHO.

According to reports received by the World Organization for Animal Health (OIE), various influenza A(H5) subtypes continue to be detected in birds in Africa, Europe and Asia.

**Influenza A(H7N9)**
Between 21 January 2018 and 12 February 2019, no new laboratory-confirmed human cases of influenza A(H7N9) virus infection were reported to WHO. There have been no publicly available reports from animal health authorities in China of influenza A(H7N9) virus detections in animals in recent months.

**Influenza A(H9N2)**
Between 21 January 2018 and 12 February 2019, 2 new laboratory-confirmed case of influenza A(H9N2) virus infection was reported to WHO, both from China. Avian influenza A(H9N2) viruses are enzootic in poultry in China.

**Influenza A(H3N2)v virus**
Between 21 January 2018 and 12 February 2019, 1 new laboratory-confirmed human case of influenza A(H3N2)v virus infection was reported from Australia.

- **Middle East respiratory syndrome coronavirus (MERS-CoV)** latest update on 13 March 2019

Up to 20 March 2019, a total of five cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (three imported and two linked cases) have been confirmed in the UK. On-going surveillance has identified
1,475 suspected cases in the UK since September 2012 that have been investigated for MERS-CoV and tested negative.

The National IHR Focal Point of The Kingdom of Saudi Arabia notified WHO of an ongoing outbreak of Middle East Respiratory Syndrome coronavirus (MERS-CoV). Between 29 January 2019 and 13 February 2019, 39 cases of MERS-CoV were reported including 4 deaths.

Between 12 February and 18 February 2019, the National IHR Focal Point of Oman reported 8 additional cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV).

Globally, since September 2012 and up to the end of February 2019, WHO has been notified of 2,374 laboratory-confirmed cases of infection with MERS-CoV, including 823 related deaths. Further information on management and guidance of possible cases is available online. The latest ECDC MERS-CoV risk assessment can be found here, where it is highlighted that risk of widespread transmission of MERS-CoV remains very low.

Acknowledgements
This report was prepared by the Influenza section, Immunisations and Countermeasures Division, National Infection Service, Public Health England. We are grateful to all who provided data for this report including the RCGP Research and Surveillance Centre, the PHE Real-time Syndromic Surveillance team, the PHE Respiratory Virus Unit, the PHE Modelling and Statistics unit, the PHE Dept. of Healthcare Associated Infection & Antimicrobial Resistance, PHE regional microbiology laboratories, Office for National Statistics, the Department of Health, Health Protection Scotland, National Public Health Service (Wales), the Public Health Agency Northern Ireland, the Northern Ireland Statistics and Research Agency, QSurveillance® and EMIS and EMIS practices contributing to the QSurveillance® database.

Related links
Sources of flu data
- Clinical surveillance through primary care in the UK
- Outbreak reporting
- FluSurvey
- MOSA
- Real time syndromic surveillance
- MEM threshold methodology paper and UK pilot paper

Disease severity and mortality data
- USISS system
- EuroMOMO mortality project

Vaccination
- Seasonal influenza vaccine programme (Department of Health Book)
- Childhood flu programme information for healthcare practitioners (Public Health England)
- 2018/19 Northern Hemisphere seasonal influenza vaccine recommendations (WHO)